奥希替尼联合铂类-培美曲塞：用于既往未治疗的EGFR突变局部晚期或转移性非小细胞肺癌的综述
Osimertinib Plus Platinum-Pemetrexed: A Review in Previously Untreated, EGFR-Mutated, Locally Advanced or Metastatic NSCLC
奥希替尼是第三代EGFR酪氨酸激酶抑制剂（靶向EGFR突变的口服靶向药）。本文综述其联合铂类-培美曲塞化疗作为EGFR外显子19缺失或21 L858R突变晚期非小细胞肺癌一线治疗的证据。关键3期FLAURA2试验显示，联合方案相比奥希替尼单药显著延长中位无进展生存期和总生存期，耐受性可控，未发现新的安全信号。结论认为该联合方案是此类患者一线治疗的有价值选择。
为什么推荐给您：对已获批联合方案的综述，属已知疗法的常规总结，无新证据。
不需要生物学背景，多打比方
正在获取全文并生成讲解（拿不到全文就依据摘要），大约需要 30–60 秒…
已等待 0 秒
这篇还没有动画
动画会把研究的流程、作用机制和关键结果一步一步演示出来，每一步都标明出自原文哪里。制作大约需要 30–60 秒。
摘要Abstract
Oral osimertinib (TAGRISSO®) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. It is approved in several countries (including China, EU, Japan and the USA) for use in combination with platinum-pemetrexed chemotherapy as first-line treatment for adult patients with advanced non-small cell lung cancer (NSCLC) (EU) or locally advanced or metastatic NSCLC (USA) whose tumours have EGFR exon 19 deletions or exon 21 L858R mutations. In the pivotal phase III FLAURA2 trial in this patient population, osimertinib plus platinum-pemetrexed significantly prolonged median progression-free survival (PFS) and overall survival (OS) compared with osimertinib monotherapy. Osimertinib plus platinum-pemetrexed had a manageable tolerability profile, with safety consistent with that of the individual agents, and no new safety signals were identified. In conclusion, osimertinib plus platinum-pemetrexed is a valuable addition to the first-line treatment options for EGFR-mutated, locally advanced or metastatic NSCLC.